TRIPLE NEGATIVE BREAST CANCER (TNBC)

This study is testing whether a combination of two drugs, sacituzumab tirumotecan and tagitanlimab, can help control advanced triple-negative breast cancer that has worsened after initial treatment. It will involve about 47 patients whose tumors test positive for a marker called …

This study is testing a new combination of three drugs for advanced triple-negative breast cancer that has progressed after initial treatment. It will enroll 12 patients to see if adding an anti-fibrosis drug (pirfenidone) to an immunotherapy (camrelizumab) and chemotherapy can h…

This study is testing whether adding a pill called everolimus after standard chemotherapy helps prevent cancer from coming back in people with early-stage triple-negative breast cancer. About 900 patients who've had surgery and chemotherapy will be randomly assigned to receive ei…

This study is testing a new combination of four drugs given before surgery for early, high-risk triple-negative breast cancer. The goal is to see if this combination can shrink or eliminate the tumor more effectively. The study will enroll 20 women to receive immunotherapy and ch…

This study aims to find the best dose of radiation to combine with standard chemotherapy and immunotherapy before surgery for an aggressive type of breast cancer that has spread to lymph nodes. It will enroll 32 patients who will be randomly assigned to receive either a low or hi…

This study aims to develop a blood test that predicts whether cancer patients will benefit from immunotherapy drugs. Researchers will analyze blood samples from 600 patients with lung cancer, melanoma, breast cancer, kidney cancer, or head/neck cancer before they start treatment.…

This early study is testing a new radioactive imaging agent called LNTH-2403 in people with advanced cancers that have spread or can't be removed. The main goals are to see if it's safe and to track where it goes in the body using special scans. Researchers want to learn if this …